Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study.

Tumor mutation burden (TMB) is an emerging prognostic biomarker of immunotherapy for bladder cancer (BLCA). We aim at investigating radiomic features’ value in predicting the TMB status of BLCA patients.